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Urinary-tract disorderPumpkin seeds have been known in folk medicine as remedy for kidney, bladder and prostate disorders since
centuries. Nevertheless, pumpkin research provides insufﬁcient data to back up traditional beliefs of ethnomed-
ical practice. The bioactivity of a hydro-ethanolic extract of pumpkin seeds from the Styrian pumpkin, Cucurbita
pepo L. subsp. pepo var. styriaca, was investigated. As pumpkin seed extracts are standardized to cucurbitin, this
compound was also tested. Transactivational activity was evaluated for human androgen receptor, estrogen re-
ceptor and progesterone receptor with in vitro yeast assays. Cell viability tests with prostate cancer cells, breast
cancer cells, colorectal adenocarcinoma cells and a hyperplastic cell line from benign prostate hyperplasia tissue
were performed. As model for non-hyperplastic cells, effects on cell viability were tested with a human dermal
ﬁbroblast cell line (HDF-5). No transactivational activity was found for human androgen receptor, estrogen
receptor and progesterone receptor, for both, extract and cucurbitin. A cell growth inhibition of ~40–50%was ob-
served for all cell lines,with the exception of HDF-5,which showedwith ~20%much lower cell growth inhibition.
Given the receptor status of some cell lines, a steroid-hormone receptor independent growth inhibiting effect can
be assumed. The cell growth inhibition for fast growing cells togetherwith the cell growth inhibition of prostate-,
breast- and colon cancer cells corroborates the ethnomedical use of pumpkin seeds for a treatment of benign
prostate hyperplasia. Moreover, due to the lack of androgenic activity, pumpkin seed applications can be
regarded as safe for the prostate.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Pumpkin1. Introduction
Pumpkins are known all over the world and belong to the family
Cucurbitaceae, which includes economically very important species.
Aqueous extracts of pumpkin seeds are used in folk medicine to treat
urinary tract complications. Hydroethanolic pumpkin seed extracts
showed promising activities on stress urinary incontinence, on urina-
tion frequency and onnocturia in clinical trials,whichdraw the research
interest to the polar part, instead of themorewell-known seed oil [1–4].
Despite the widespread use, effects on cell growth and receptor in-
teraction are not known. Pumpkins are consumed mostly as food, but
Cucurbitaceae representatives are also used in several countries such
as Mexico, North India, China, and in the Caribbean, in ethnomedicinal
applications [5–9]. In Central Europe, pumpkin seeds are recommended
for bladder and prostate problems and several dietary supplements areMedjakovic),
i-graz.at
ar), alois.jungbauer@boku.ac.at
. This is an open access article undercommercially available for this purpose. Pumpkins are also used for
prostate problems in the Caribbean area [7]. In Austria a special variety,
the Styrian oil pumpkin, Cucurbita pepo L. subsp. pepo var. styriaca, had
been grown for decades [10] and is also used as food supplement.
Nevertheless, the bioactive properties of pumpkins have been barely
investigated. In addition, pumpkin seeds are often tested in a complex
mixture with other plants and ingredients. For example, Jiang et al.
[11,12] demonstrated inhibition of prostate cancer in vitro and in a xe-
nograft model with a polyherbal dietary supplement where pumpkin
seeds are only one of 33 ingredients. This makes an interpretation of
the efﬁcacy of individual extracts and compounds impossible.
In a randomized, double-blind, placebo-controlled trial with 47 be-
nign prostatic hyperplasia patients, international prostate symptom
score (IPSS) was reduced by a 3 months treatment with pumpkin seed
oil, but prostate speciﬁc antigen and prostate volumewere not reduced
[13]. IPSS is a standardized questionnaire that is used to evaluate symp-
toms of benign prostate hyperplasia. Another clinical trialwith 2245 pa-
tients with benign prostate hyperplasia, who received during 3 months
an ethanolic pumpkin seed extract, resulted also in an efﬁcient im-
provement of BPH symptoms, especially in early stages, which was
measured with a decreased IPSS [14].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Cucurbitin in yeast androgen assay. 5-alpha-Dihydrotestosterone (5a-DHT) was
the reference compound and DMSO was used as negative control. Mean values ± SD are
given. Experiments were performed in at least three independent assays and within
these tests in at least duplicates.
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but mostly with pumpkin seed oil; these studies show a benevolent im-
pact on prostate via inhibition of testosterone-induced hyperplasia [15,
16].
Another possibility to prevent an immense growth of hyperplastic
tissue could be obtained by cytotoxic effects. Cytotoxic activity was
reported for ﬁg-leaf gourd (Cucurbita ﬁcifolia), a Cucurbitaceae
species that is common in Mexico [17]. This was also reported for
compounds such as cucurbitacins, moschatin and cucurmosin from
other Cucurbitaceae species [18–21].
Nevertheless, these studies present only a small glimpse in the po-
tential of Cucurbitaceae as therapeutic and do not explain satisfactorily
traditional ethnomedical applications. More studies are needed to cor-
roborate ethnopharmacological records or to dismiss them. In this
study, we tested two effects of pumpkin seed extract and cucurbitin,
(3R)-3-aminopyrrolidine-3-carboxylic acid, that is used to standardize
this extract. In the ﬁrst place the transactivation of human androgen re-
ceptor, estrogen receptor α and progesterone receptor has been tested,
and secondly the impact on cell viability of several cancer cell lines, a hy-
perplastic cell line and a normal ﬁbroblastic cell line has been evaluated.
Experiments with an androgen-sensitive and an androgen-insensitive
prostate cancer cell line were performed to test if possible effects are
mediated by an androgen-dependent route. Experiments were per-
formed in at least three independent assays and within these tests in
at least duplicates.Fig. 2. Crude pumpkin seed extract and extracts of the granulated extract inDMSOand
water in yeast androgen assay. 5 alpha-Dihydrotestosterone (5a-DHT)was the reference
compound andDMSOwas usedas negative control. Extractswere testedwith andwithout
ONPGas substrate. Sample code: K..pumpkin seed, R..crude extract, G..granulate (pumpkin
seed extract on maltodextrin), D..extract or dilution with DMSO, W..extract or dilution
with destilled water. Crude extract was tested undiluted and in dilutions 1:2 (KRD2 or
KRW2), 1:5 (KRD5 or KRW5) and 1:10 (KRD10 or KRW10). The extract granulate was
tested after extraction with DMSO or water in concentrations of 500 mg/ml (KGD500 or
KGW500), 100 mg/ml (KGD100 or KGW100), 50 mg/ml (KGD50 or KGW50), 20 mg/ml
(KGD20 or KGW20) and 10 mg/ml (KGD10 or KGW10). Mean values ± SD are given.
Experiments were performed in at least three independent assays and within these tests
in at least duplicates.2. Materials and methods
2.1. Chemicals and media
Dimethyl sulfoxide (DMSO), 17β-estradiol (E2), β-naphthoﬂavone,
5α-dihydrotestosterone (5α-DHT), N-lauroylsarcosine (sodium salt),
disodium hydrogen phosphate dihydrate (Na2HPO4 ∗ 2 H2O), sodium
dihydrogen phosphate dihydrate (NaH2PO4 ∗ 2 H2O), potassium chlo-
ride (KCl), magnesium sulfate heptahydrate (MgSO4 ∗ 7 H2O), sodium
carbonate (Na2CO3), copper(II) sulfate pentahydrate (CuSO4 ∗ 5 H2O)
and o-nitrophenyl-β-galactopyranoside (ONPG) were purchased from
Sigma Aldrich (St. Louis, MO, USA), Fluka (Buch, Switzerland), and
Merck (Darmstadt, Germany). Cucurbitin was purchased from Phytolab
(Vestenbergsgreuth, Germany).
For yeast media preparation, yeast nitrogen base was purchased
from Difco (Franklin Lakes, NJ), amino acids from Serva Feinbiochemica
(Heidelberg, Germany), and dropout mediumwithout tryptophan from
Sigma Aldrich. Cell culture media and reagents were purchased fromBiochrom (Berlin, Germany), Sigma-Aldrich or Invitrogen (Lofer,
Austria).
Cell culture reagents were purchased from Biochrom (Berlin,
Germany), Sigma-Aldrich (St. Louis, MO, USA) or Invitrogen (Lofer,
Austria). Sodium selenite, human transferrin, methylthiazolyldiphenyl-
tetrazolium bromide (MTT), staurosporine and insulin (solution from
bovine pancreas) was purchased from Sigma-Aldrich (St. Louis, MO,
USA).2.2. Extracts
The pumpkin seed extracts were kindly provided by APOMEDICA
Pharmazeutische Produkte GmbH (Graz, Austria). The crude extract is
a hydroethanolic extract (60%) of Cucurbita pepo L. ssp. pepo var. styriaca
semen with a drug:extract ratio of 15–25:1. The content of cucurbitin
measured by GC was 0.41% (m/m).
A second batch of the extract was granulated onmaltodextrin (30%)
as carrier.
The crude extract was diluted with distilled water (sterile ﬁltered,
0.22 μm ﬁlters from Millipore (Millipore Ireland Ltd.) or with DMSO in
dilutions 1:2 (KRD2 or KRW2), 1:5 (KRD5 or KRW5) and 1:10 (KRD10
or KRW10). The extract granulate was extracted with DMSO or water
in concentrations of 500 mg/ml (KGD500 or KGW500), 100 mg/ml
(KGD100 or KGW100), 50 mg/ml (KGD50 or KGW50), 20 mg/ml
(KGD20 or KGW20) and 10 mg/ml (KGD10 or KGW10).2.3. Cell lines
Du-145 was obtained by ATCC (Wesel, Germany). LnCaP and BPH-1
were purchased by DSMZ (Braunschweig, Germany). Caco-2 andMCF-7
were kindly provided by Manfred Schuster (Apeiron Biologics, Vienna,
Austria). HDF-5 was provided by the Cell culture working group of the
department of biotechnology (Vienna, Austria).
Fig. 5. Cucurbitin in yeast progesteron receptor assay. Progesterone was the reference
compound and DMSO was used as negative control. Mean values ± SD are given.
Experiments were performed in at least three independent assays and within these tests
in at least duplicates.
Fig. 3. Cucurbitin in yeast estrogen receptor alpha assay. 17β-Estradiol (E2) was the
reference compound and DMSO was used as negative control. Mean values ± SD are
given. Experiments were performed in at least three independent assays and within
these tests in at least duplicates.
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Yeast assay performance and evaluation of the assays with the
human androgen receptor (yAS), estrogen receptor α (yESα) and
progesterone receptor (yPR) have been previously described by
Reiter et al. [22]. They are two-plasmid systems containing expres-
sion plasmids with the appropriate human receptor gene (AR, ERα
or PR) and a LacZ reporter plasmid. The expression of the expression
plasmid is induced upon addition of copper. If an agonist of the ap-
propriate receptor is present, the hormone receptor is activated
and binds as homodimer to a hormone response element (HRE) on
the reporter plasmid. The gene product of the reporter plasmid isFig. 4. Crude pumpkin seed extract and extracts of the granulated extract in DMSOand
water in yeast estrogen receptor alpha assay. 17β-Estradiol (E2) was the reference
compound and DMSO was used as negative control. Extracts were tested with and
without ONPG as substrate. Sample code: K..pumpkin seed, R..crude extract, G..granulate
(pumpkin seed extract on maltodextrin), D..extract or dilution with DMSO, W..extract or
dilution with destilled water. Crude extract was tested undiluted and in dilutions 1:2
(KRD2 or KRW2), 1:5 (KRD5 or KRW5) and 1:10 (KRD10 or KRW10). The extract
granulate was tested after extraction with DMSO or water in concentrations of 500 mg/
ml (KGD500 or KGW500), 100 mg/ml (KGD100 or KGW100), 50 mg/ml (KGD50 or
KGW50), 20 mg/ml (KGD20 or KGW20) and 10 mg/ml (KGD10 or KGW10). Mean
values ± SD are given. Experiments were performed in at least three independent
assays and within these tests in at least duplicates.β-galactosidase, which is quantiﬁed and measured for the agonistic
effect of the ligand. The speciﬁc enzyme activity, expressed in Miller
Units (MU), is the β-galactosidase activity normalized to the optical
density at a wavelength of 600 nm. For the evaluation, the MU was
plotted against the concentration (logarithmic scaling) and the
resulting curve ﬁtted using a logistic dose response function. The cal-
culation and ﬁtting was performed using Table Curve 2D software
(Jandel Scientiﬁc) and plotted with SigmaPlot 10.0 (Systat Soft-
ware). Miller Units were normalized to the maximum of the refer-
ence compound (sum of parameters a and b of the logistic response
curve, which represent the baseline and the plateau of the curve;
set to 100%).Fig. 6. Crude pumpkin seed extract and extracts of the granulated extract inDMSOand
water in yeast progesterone receptor assay. Progesteron was the reference compound
and DMSO was used as negative control. Extracts were tested with and without ONPG
as substrate. Sample code: K..pumpkin seed, R..crude extract, G..granulate (pumpkin
seed extract on maltodextrin), D..extract or dilution with DMSO, W..extract or dilution
with destilled water. Crude extract was tested undiluted and in dilutions 1:2 (KRD2 or
KRW2), 1:5 (KRD5 or KRW5) and 1:10 (KRD10 or KRW10). The extract granulate was
tested after extraction with DMSO or water in concentrations of 500 mg/ml (KGD500 or
KGW500), 100 mg/ml (KGD100 or KGW100), 50 mg/ml (KGD50 or KGW50), 20 mg/ml
(KGD20 or KGW20) and 10 mg/ml (KGD10 or KGW10). Mean values ± SD are given.
Experiments were performed in at least three independent assays and within these tests
in at least duplicates.
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Human prostate cancer cell lines LNCaP (androgen sensitive)
and DU145 (androgen insensitive), human breast cancer cell line
MCF-7 (ERα positive) human epithelial colorectal adenocarcinoma
cell line Caco-2, human benign prostate hyperplasia cell line BPH-1
and human dermal ﬁbroblasts were cultured in appropriate media
(LNCaP: RPMI 1640 w/o phenolred +10% FCS; DU145: RPMI
1640 + 10% FCS; MCF-7: MEM Earl's Salt +2 mM L-alanyl gluta-
mine, 1 mM sodium-pyruvate, 1× non-essential amino acid solu-
tion, 0.01 mg/ml bovine insulin and 10% FCS; Caco-2: MEM Earl's
Salt +2 mM L-glutamine, 1 mM sodium-pyruvate, 1× non-
essential amino acid solution and 20% FCS; BPH-1: RPMI
1640 + 5 μg/ml transferrin, 5 ng/ml sodium selenite and 5 μg/ml
insulin) and incubated at 37 °C and 5% CO2 and humidiﬁed atmo-
sphere. Media were replaced every 2–3 days, depending on growth
rate.Fig. 7. Effects of hydroalcoholic pumpkin seed extracts and cucurbitin on growth of can
receptor sensitive prostate cancer cell line LNCaP, (c) androgen receptor in sensitive prostate
as positive control. Sample code: K..pumpkin seed, R..crude extract, G..granulate (pumpkin see
distilled water. Crude extract was tested undiluted and in dilutions 1:2 (KRD2 or KRW2), 1:5
in concentrations of 500 mg/ml (KGD500 or KGW500), and 100 mg/ml (KGD100 or KGW
independent assays and within these tests in at least duplicates.2.6. Cell viability assay (MTT assay)
Cellswere trypsinized, harvested and diluted to aﬁnal concentration
of 105 cells/ml. 100 μl cell suspension were applied per well (96 well
plates, sterile, transparent, ﬂat bottom, from Nunc (Roskilde,
Denmark)) and incubated at 37 °C and 5% CO2 for 24 h. Media
were removed and 198 μl of fresh media were added to the adhered
cells. 2 μl of sample were applied in each well. Staurosporine (end
concentration of 10 μM) that induces apoptosis was used as positive
control. Cells only with DMSO as vehicle in media are the reference.
Each test set-up consisted of three microtiter plates. After 24 h 20 μL
MTT-solution (5 g/L methylthiazolyldiphenyl-tetrazolium bromide
in PBS) were added to each well of the ﬁrst plate, incubated for 2 h
at 37 °C and the media was removed. 100 μL DMSO was added to
each well and mixed for 5 min. The absorbance of the dissolved pur-
ple formazan complex that is a measure of cell growth and prolifer-
ation activity was measured with a Tecan Genios Pro plate reader atcer cell lines. (a) Estrogen receptor positive breast cancer cell line MCF-7, (b) androgen
cancer cell line DU-145, and (d) colon cancer cell line (Caco-2). Staurosporine was tested
d extract on maltodextrin), D..extract or dilution with DMSO, W..extract or dilution with
(KRD5 or KRW5). The extract granulate was tested after extraction with DMSO or water
100). Mean values ± SD are given. Experiments were performed in at least three
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cedure was repeated with the second microtiter plate of the test run
and after 72 h with the third microtiter plate. Results were related to
absorbance of untreated cells (reference).
The relative growth inhibition was calculated as:
Cellgrowthrelated to control ¼ Absorbanceof extract of cellswithtreatmentAbsorbanceof extract of cellswithout treatment.
To evaluate the sensitivity index, cell viability assays with HDF-
5 treated with crude pumpkin seed extract were conducted with
varying end concentrations of extract (100 μg/mL, 150 μg/mL,
200 μg/mL, 250 μg/mL, 350 μg/mL, 400 μg/mL and 500 μg/mL).3. Results and discussion
3.1. Androgen receptor yeast assay (yAS)
Curcubitin, a lead compound in hydroalcoholic extracts, did not
transactivate the androgen receptor (Fig. 1).
The crude pumpkin seed extract and low dilutions (KRW2 and
KRD2) thereof and high concentrations of the granulated extract
(KGD500 and KGW500), showed a low signal above the blank. The
signal was in the same range as 5-alpha-dihydrotestosterone at
5 nM ﬁnal concentration (Fig. 2). But as the pumpkin extracts
have a relatively strong intrinsic colour, an experiment was set up,
where extracts and dilutions were tested in parallel with and with-
out ONPG as substrate, to eliminate false-positive results. The nor-
mal yeast assay set-up is so designed that upon transactivation of
the receptor, a reporter plasmid is expressed with β-galactosidase
as gene product. This enzyme hydrolyses the substrate ONPG into
among others ortho-nitrophenol, which gives a yellow colour.
When no ONPG is present and still a signal is detected at the wave-
length that is measured for the test, it is a false positive result due to
intrinsic coloration of the sample. This is true for pumpkin seed
extract; with and without ONPG as substrate, the same signal is
detected (Fig. 2).Fig. 8. Effects of hydroalcoholic pumpkin seed extracts on growth of non-transformed hu
(BPH-1) (b). Staurosporine was tested as positive control. Sample code: K..pumpkin seed, R..c
with DMSO, W..extract or dilution with distilled water. Crude extract was tested undiluted
tested after extraction with DMSO or water in concentrations of 500 mg/ml (KGD500 or KGW
were performed in at least three independent assays and within these tests in at least duplicat3.2. Estrogen receptor α yeast assay (yESα)
Curcubitin showed also no estrogenic activity in yeast assay (Fig. 3).
Similar as in the yeast androgen receptor assay, pumpkin seed ex-
tracts showed in high concentrations or in low dilutions of the crude ex-
tract, low signal in the yeast estrogen α receptor assay. This signal is in
the range of 0.172 nM 17β-estradiol, which was the reference com-
pound of the assay. Nevertheless, like in the androgen receptor assay,
this signal is due to a false-positive result arising from the strong intrin-
sic colour of the extracts (Fig. 4).
3.3. Progesterone receptor yeast assay (yPR)
Curcubitin showed also no activity in the yeast assaywith progester-
one receptor (Fig. 5).
The same results were obtained as in yAS and yESα. Pumpkin seed
extracts showed in high concentrations or in low dilutions of the
crude extract, low signalling in yPR (Fig. 6), but the experiment with
and without substrate showed that this is a false-positive result.
3.4. Cell viability assays
Crude pumpkin seed extract inhibited the cell growth in all cancer
cell lines, being both prostate cancer cell lines, the androgen-sensitive
LNCaP and the androgen-insensitive DU-145, the estrogen-receptor
positive breast cancer cell line MCF-7 and the colorectal adenocarcino-
ma cell line Caco-2 (Fig. 7). This effect was not due to cucurbitin, as
this compound showed no growth inhibiting effect on cancer cell lines
(Fig. 7).
The growth inhibition was also observed in the hyperplastic, but
non-carcinogenic cell line BPH-1,which stems from benign prostate hy-
perplasia tissue (Fig. 8). For cancer cell lines and BPH-1, a cell growth in-
hibition of about 40–50%was observed. The cell growth inhibiting effect
was less in the human ﬁbroblast cell line HDF-5, where only an inhibi-
tion of ~20% was observed (Fig. 8).
To investigate the sensitivity index of pumpkin seed extract, HDF-5
were treated with varying end concentrations of crude pumpkin seedman dermal ﬁbroblasts (HDF-5) (a) and human benign prostate hyperplasia cell line
rude extract, G..granulate (pumpkin seed extract on maltodextrin), D..extract or dilution
and in dilutions 1:2 (KRD2 or KRW2), 1:5 (KRD5 or KRW5). The extract granulate was
500), and 100 mg/ml (KGD100 or KGW100). Mean values ± SD are given. Experiments
es. Abbreviations: n.t., not tested.
Fig. 9. Comparison of growth inhibition of crude pumpkin seed extract between non-
transformed human dermal ﬁbroblasts (HDF-5 cell line), human benign prostate
hyperplasia cell line (BPH-1) and cancer cell lines (human prostate cancer cell line
LNCaP (androgen sensitive), DU-145 (androgen insensitive), human breast cancer
cell line MCF-7 (ERalpha positive) and human epithelial colorectal adenocarcinoma
cell line Caco-2). Staurosporine was tested as positive control. Mean values ± SD are
given. Experiments were performed in at least three independent assays and within
these tests in at least duplicates.
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400 μg/mL and 500 μg/mL) and compared to the effect of 100 μg/mL
crude pumpkin seed extract on all other cell lines. A dose-dependent
decrease of cell viability can be observed, with IC50 values (mean ±
S.E.M) of 177.05 ± 38.22 μg/mL after 24 h, 189.41 ± 11.44 μg/mL after
48 h and 192.22 ± 18.51 after 72 h. In direct comparison, it can be
seen that a 1.5 to 2fold concentration of the extract is necessary to elicit
the same effect on HDF-5 as on the cancer cell lines or BPH-1 (Fig. 9).
Testing three different batches of crude pumpkin seed extracts did
not show a variation. Only one cell line (BPH-1) was used for this pur-
pose (Fig. 10).
4. Conclusions
Ethnomedicine represents a treasure trove formodernmedicine and
pharmaceutical industry. The oral traditions and the experience ofFig. 10. Testing of batch to batch variability of crude pumpkin extraction on growth
inhibition of human benign prostate hyperplasia cell line (BPH-1). Staurosporine
was tested as positive control. Mean values ± SD are given. Experiments were
performed in at least three independent assays and within these tests in at least
duplicates.healers that have been collected over the centuries have great potential.
Butmodern research has to investigate if ethnomedicinal records have a
scientiﬁc basis.
Pumpkin is a vegetable that is consumed all over the world as food.
But especially pumpkin seeds have also been used in traditional medi-
cineworldwide. Unfortunately, studies that investigate this plant mate-
rial are scarce and data are insufﬁcient to draw a deﬁnite conclusion
about the efﬁcacy of pumpkin seeds for the treatment or prevention of
diseases.
Pumpkin seeds are used in Central Europe as remedy for benign
prostate hyperplasia and bladder problems. Especially in Austria, a spe-
cial variety is well known. The Styrian oil pumpkin (Cucurbita pepo L.
subsp. pepo var. styriaca) is unique among pumpkins as the seeds of
this variety have no outer shell due to a mutation. The famous Styrian
pumpkin seed oil is produced from these seeds after roasting. But not
only the oil, also have hydroethanolic extracts been associated with
beneﬁcial health effects. Our studies clearly show that these effects are
not mediated through sex steroid hormone receptors. Prostate hyper-
plasia has been associated with aberration in regulation of steroid hor-
mone receptors. Thus it is obvious to test if these extracts are able to
modulate steroid hormone pathway. Hydroalcoholic pumpkin seed ex-
tract inhibits growth of cancer cells but also hyperplastic cells, while its
effects on non-hyperplastic cells are much weaker. This effect is of high
signiﬁcance. Every compound that is able to be more effective against
hyperplastic cells such as cancer cells or fast growing cells found for ex-
ample in prostatic hyperplasia tissue, and be only moderate effective
against non-hyperplastic cells, provides new therapeutic opportunities.
Hence, if our in vitro results were to be mirrored in vivo, pumpkin ex-
tractwould be truly an interesting tool at least as accompanying remedy
for example for benign prostate hyperplasia, a common disease in men
over ﬁfty years of age. This in vitro evidence also corroborates the obser-
vation in the clinical study of Friedrich at al. [14] and experience in eth-
nomedicine. The extract used in this study shows a high drug:extract
ratio of 15–25:1, hence we consider it preferable to use an extract in-
stead of crude plantmaterial to get rational and relevant concentrations.
Our study indicates that the effect is not mediated by cucurbitin, the
lead compound used for standardisation of such extracts. We also show
that different batches of pumpkin seed extract have the same in vitro
properties in cell culture. Although the compoundwhich is used to stan-
dardize the extract is not our active ingredient for the effects thatwe ob-
served,we can conclude that the standardized production of this extract
is nevertheless efﬁcient. In this case the often criticised shortcoming of
plant extracts, namely being poorly standardized, has been overcome.
In general, the active ingredients of phytopharmaceuticals as used in
ethnomedicine are mostly unknown and the plant extract as such is
considered as active ingredient. Often it is a mixture of active com-
pounds and their concerted action that mediates pharmaceutical activ-
ity. Nevertheless, the isolation of active compounds should be the next
step in order to elucidate the phytochemical basis of the growth inhib-
itory effects observed in the current study.
Conﬂict of interest
The study was in part sponsored by the Christian-Doppler-
Laboratory of Receptor Biotechnology (70%) and by APOMEDICA
Pharmaceutical Products GmbH (30%). These funding sources had
no involvement in study design, in the collection, analysis and inter-
pretation of data, in the writing of themanuscript and in the decision
to submit the article for publication. The authors have indicated that
they have no other conﬂicts of interest regarding the content of this
article.
References
[1] B. Shim, H. Jeong, S. Lee, S. Hwang, B. Moon, C. Storni, A randomized double-blind
placebo-controlled clinical trial of a product containing pumpkin seed extract and
156 S. Medjakovic et al. / Fitoterapia 110 (2016) 150–156soy germ extract to improve overactive bladder-related voiding dysfunction and
quality of life, J. Funct. Foods 8 (2014) 111–117.
[2] H. Sogabe, T. Terado, Open clinical study of effects of pumpkin seed extract/soybean
germ extract mixture-containing processed food on nocturia, Jpn. J. Med. Pharm. Sci.
46 (2001) 727–737.
[3] T. Terado, H. Sogabe, K. Saito, Clinical study of mixed processed foods containing of
pumpkin seed extract and soybean germ extract on pollakiuria in night in elder
men, Jpn. J. Med. Pharm. Sci. 52 (2004) 551–561.
[4] E. Yanagisawa, I. Satoh, Clinical study of mixed processed foods containing of pump-
kin seed extract and soybean germ extract on stress urinary incontinence (SUI) in
women, Jpn. J. Med. Pharm. Sci. 50 (2003) 313–322.
[5] H. Aggarwal, N. Kotwal, Foods used as ethno-medicine in Jammu, Ethno-Med. 3
(2009) 65–68.
[6] W. Jia, W. Gao, L. Tang, Antidiabetic herbal drugs ofﬁcially approved in China,
Phytother. Res. 17 (2003) 1127–1134.
[7] C. Lans, Ethnomedicines used in Trinidad and Tobago for reproductive problems, J.
Ethnobiol. Ethnomed. 3 (2007) 13.
[8] T.K. Lim, Edible Medicinal and Non-Medicinal Plants: Volume 2, Fruits, Springer,
2012.
[9] F.J. Alarcon-Aguilar, E. Hernandez-Galicia, A.E. Campos-Sepulveda, S. Xolalpa-
Molina, J.F. Rivas-Vilchis, L.I. Vazquez-Carrillo, R. Roman-Ramos, Evaluation of the
hypoglycemic effect of Cucurbita ﬁcifolia Bouche (Cucurbitaceae) in different exper-
imental models, J. Ethnopharmacol. 82 (2002) 185–189.
[10] H. Teppner, Cucurbita pepo (Cucurbitaceae) — history, seed coat types, thin coated
seeds and their genetics, Phyton – Ann. Rei Bot. 40 (2000) 1–42.
[11] J. Jiang, I. Eliaz, D. Sliva, Suppression of growth and invasive behavior of human pros-
tate cancer cells by ProstaCaid: mechanism of activity, Int. J. Oncol. 38 (2011)
1675–1682.
[12] J. Jiang, J. Loganathan, I. Eliaz, C. Terry, G.E. Sandusky, D. Sliva, ProstaCaid inhibits
tumor growth in a xenograft model of human prostate cancer, Int. J. Oncol. 40
(2012) 1339–1344.[13] H. Hong, C.S. Kim, S. Maeng, Effects of pumpkin seed oil and saw palmetto oil in Ko-
rean men with symptomatic benign prostatic hyperplasia, Nutr. Res. Pract. 3 (2009)
323–327.
[14] M. Friederich, C. Theurer, G. Schiebel-Schlosser, Prosta Fink Forte capsules in the
treatment of benign prostatic hyperplasia. Multicentric surveillance study in 2245
patients, Forsch. Komplementarmed. Klass. Naturheilkd. 7 (2000) 200–204.
[15] M. Gossell-Williams, A. Davis, N. O'Connor, Inhibition of testosterone-induced hy-
perplasia of the prostate of sprague-dawley rats by pumpkin seed oil, J. Med. Food
9 (2006) 284–286.
[16] Y.S. Tsai, Y.C. Tong, J.T. Cheng, C.H. Lee, F.S. Yang, H.Y. Lee, Pumpkin seed oil and
phytosterol-F can block testosterone/prazosin-induced prostate growth in rats,
Urol. Int. 77 (2006) 269–274.
[17] E. Vega-Avila, A. Espejo-Serna, F. Alarcon-Aguilar, R. Velasco-Lezama, Cytotoxic ac-
tivity of four Mexican medicinal plants, Proc. West. Pharmacol. Soc. 52 (2009)
78–82.
[18] B. Jayaprakasam, N.P. Seeram, M.G. Nair, Anticancer and antiinﬂammatory activities
of cucurbitacins from Cucurbita andreana, Cancer Lett. 189 (2003) 11–16.
[19] H.C. Xia, F. Li, Z. Li, Z.C. Zhang, Puriﬁcation and characterization of Moschatin, a novel
type I ribosome-inactivating protein from the mature seeds of pumpkin (Cucurbita
moschata), and preparation of its immunotoxin against human melanoma cells,
Cell Res. 13 (2003) 369–374.
[20] B. Zhang, H. Huang, J. Xie, C. Xu, M. Chen, C. Wang, A. Yang, Q. Yin, Cucurmosin in-
duces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the
EGFR signaling pathway, Oncol. Rep. 27 (2012) 891–897.
[21] J. Xie, W. Que, H. Liu, M. Liu, A. Yang, M. Chen, Anti-proliferative effects of
cucurmosin on human hepatoma HepG2 cells, Mol. Med. Rep. 5 (2012) 196–201.
[22] E. Reiter, V. Beck, S. Medjakovic, M. Mueller, A. Jungbauer, Comparison of hormonal
activity of isoﬂavone-containing supplements used to treat menopausal complaints,
Menopause 16 (2009) 1049–1060.
